MNKD
Price
$5.04
Change
+$0.06 (+1.20%)
Updated
Mar 11, 02:52 PM (EDT)
Capitalization
1.51B
57 days until earnings call
PGEN
Price
$1.71
Change
-$0.06 (-3.39%)
Updated
Mar 11, 03:05 PM (EDT)
Capitalization
516.91M
57 days until earnings call
Ad is loading...

MNKD vs PGEN

Header iconMNKD vs PGEN Comparison
Open Charts MNKD vs PGENBanner chart's image
MannKind
Price$5.04
Change+$0.06 (+1.20%)
Volume$300
Capitalization1.51B
Precigen
Price$1.71
Change-$0.06 (-3.39%)
Volume$500
Capitalization516.91M
MNKD vs PGEN Comparison Chart
Loading...
MNKD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MNKD vs. PGEN commentary
Mar 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MNKD is a Buy and PGEN is a Hold.

Ad is loading...
COMPARISON
Comparison
Mar 11, 2025
Stock price -- (MNKD: $4.99 vs. PGEN: $1.76)
Brand notoriety: MNKD and PGEN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MNKD: 135% vs. PGEN: 47%
Market capitalization -- MNKD: $1.51B vs. PGEN: $516.91M
MNKD [@Biotechnology] is valued at $1.51B. PGEN’s [@Biotechnology] market capitalization is $516.91M. The market cap for tickers in the [@Biotechnology] industry ranges from $383.59B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MNKD’s FA Score shows that 1 FA rating(s) are green whilePGEN’s FA Score has 0 green FA rating(s).

  • MNKD’s FA Score: 1 green, 4 red.
  • PGEN’s FA Score: 0 green, 5 red.
According to our system of comparison, MNKD is a better buy in the long-term than PGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MNKD’s TA Score shows that 4 TA indicator(s) are bullish while PGEN’s TA Score has 5 bullish TA indicator(s).

  • MNKD’s TA Score: 4 bullish, 5 bearish.
  • PGEN’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, PGEN is a better buy in the short-term than MNKD.

Price Growth

MNKD (@Biotechnology) experienced а -2.73% price change this week, while PGEN (@Biotechnology) price change was +5.69% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.68%. For the same industry, the average monthly price growth was -9.30%, and the average quarterly price growth was -8.75%.

Reported Earning Dates

MNKD is expected to report earnings on May 07, 2025.

PGEN is expected to report earnings on May 07, 2025.

Industries' Descriptions

@Biotechnology (-0.68% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MNKD($1.51B) has a higher market cap than PGEN($517M). PGEN YTD gains are higher at: 57.589 vs. MNKD (-22.395). MNKD has higher annual earnings (EBITDA): 68.8M vs. PGEN (-136.11M). MNKD has more cash in the bank: 252M vs. PGEN (28.6M). PGEN has less debt than MNKD: PGEN (5.75M) vs MNKD (240M). MNKD has higher revenues than PGEN: MNKD (267M) vs PGEN (3.96M).
MNKDPGENMNKD / PGEN
Capitalization1.51B517M292%
EBITDA68.8M-136.11M-51%
Gain YTD-22.39557.589-39%
P/E Ratio49.90N/A-
Revenue267M3.96M6,737%
Total Cash252M28.6M881%
Total Debt240M5.75M4,175%
FUNDAMENTALS RATINGS
MNKD vs PGEN: Fundamental Ratings
MNKD
PGEN
OUTLOOK RATING
1..100
1074
VALUATION
overvalued / fair valued / undervalued
1..100
62
Fair valued
73
Overvalued
PROFIT vs RISK RATING
1..100
30100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
9690
P/E GROWTH RATING
1..100
96100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MNKD's Valuation (62) in the Biotechnology industry is in the same range as PGEN (73) in the null industry. This means that MNKD’s stock grew similarly to PGEN’s over the last 12 months.

MNKD's Profit vs Risk Rating (30) in the Biotechnology industry is significantly better than the same rating for PGEN (100) in the null industry. This means that MNKD’s stock grew significantly faster than PGEN’s over the last 12 months.

PGEN's SMR Rating (97) in the null industry is in the same range as MNKD (100) in the Biotechnology industry. This means that PGEN’s stock grew similarly to MNKD’s over the last 12 months.

PGEN's Price Growth Rating (90) in the null industry is in the same range as MNKD (96) in the Biotechnology industry. This means that PGEN’s stock grew similarly to MNKD’s over the last 12 months.

MNKD's P/E Growth Rating (96) in the Biotechnology industry is in the same range as PGEN (100) in the null industry. This means that MNKD’s stock grew similarly to PGEN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MNKDPGEN
RSI
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
70%
Bullish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
72%
Bearish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
75%
Bullish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
73%
Bullish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 7 days ago
85%
Declines
ODDS (%)
Bearish Trend 13 days ago
79%
Bearish Trend 2 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
86%
Aroon
ODDS (%)
Bearish Trend 2 days ago
66%
Bullish Trend 2 days ago
85%
View a ticker or compare two or three
Ad is loading...
MNKD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYLGX95.99N/A
N/A
Rydex S&P 500 Pure Growth A
BAQAX11.99N/A
N/A
Brown Advisory Emgerg Mkts Select Adv
ILGGX20.55N/A
N/A
Columbia Integrated Large Cap Gr Instl
RDWFX10.90-0.24
-2.15%
American Funds Dvlpg Wld Gr&Inc R5
PJFQX63.29-2.82
-4.27%
PGIM Jennison Growth R6

MNKD and

Correlation & Price change

A.I.dvisor indicates that over the last year, MNKD has been loosely correlated with VCYT. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if MNKD jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNKD
1D Price
Change %
MNKD100%
+0.20%
VCYT - MNKD
44%
Loosely correlated
-5.09%
LXRX - MNKD
42%
Loosely correlated
-8.17%
INSM - MNKD
40%
Loosely correlated
-2.43%
BLUE - MNKD
38%
Loosely correlated
-1.50%
AMRN - MNKD
36%
Loosely correlated
-12.23%
More

PGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, PGEN has been loosely correlated with RCKT. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if PGEN jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PGEN
1D Price
Change %
PGEN100%
-5.11%
RCKT - PGEN
43%
Loosely correlated
-2.05%
ARWR - PGEN
41%
Loosely correlated
-10.31%
ALEC - PGEN
41%
Loosely correlated
-3.47%
NKTX - PGEN
41%
Loosely correlated
-2.72%
IDYA - PGEN
41%
Loosely correlated
-4.98%
More